Suppression Of Uveitis By A STAT3 Single Domain Antibody
Summary:
The National Eye Institute seeks research co-development partners and/or licensees for a STAT3 antibody that can suppress uveitis.
TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A
Summary:
The National Eye Institute seeks research co-development partners and/or licensees for an adeno-associated viral gene therapy for Oculocutaneous Albinism type 1A.
Using Artificial Intelligence To Diagnose Uveitis
Summary:
The National Eye Institute seeks research co-development partners and/or licensees for a deep learning algorithm that can identify retinal vasculitis using color fundus images.
Description of Technology:
Uveitis is caused by inflammation in the eye that can cause pain and reduce vision. The rate of uveitis in the United States is 1 in every 200 people with eye-related irritation. Permanent symptoms such as vision loss can occur if untreated. Therefore, early detection is crucial.
Improved Methods For Cryopreservation Of Cells, Tissues, And Organs
Summary:
The National Eye Institute seeks research co-development partners and/or licensees for novel methods of cryopreserving cells, tissues, and organs via FOXO1 activation and other mechanisms.
Interleukin-27 Producing B-Cell Population and Uses Thereof
Summary:
The National Eye Institute (NEI) seeks research co-development partners and/or licensees to advance the production and uses of interleukin-27 (IL-27) producing B-regulatory cell (i27-Breg) therapy for immune related autoimmune disorders. These disorders include but are not limited, to age-related macular degeneration (AMD), graft-versus-host disease (GVHD), multiple sclerosis (MS) and transplant rejection.
Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration
Summary:
The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations.
Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration
Description of Technology:
Axonal injury and subsequent neuronal death underpin the pathology of many neurological disorders from acute neural injuries (motor vehicle crashes, combat related injuries, traumatic brain injuries) to neurological diseases (multiple sclerosis, glaucoma). In the central nervous system (CNS), microglia help respond to CNS injuries by mediating the immune response and increasing inflammation at the site of injury.
Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration
Summary:
The National Eye Institute seeks research co-development partners and/or licensees for a deep learning algorithm that can predict the probability of progression to late age-related macular degeneration.
MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE
Summary:
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases.
Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method
Summary:
Inventors at the National Eye Institute are seeking research and co-development partners and/or licensees to: (1) advance the production and uses of the new RNA preparation method, (2) manufacture reagent kits for testing in patients with suspected COVID-19 and other DNA/RNA viruses, and (3) manufacture reagent kits for patient biomarker profiles and inherited disease diagnostics.